EXECUTIVE TEAM

James Harrison founded Cycle Pharmaceuticals in 2012. James was formerly CEO of Archimica, an international contract manufacturing organisation of active pharmaceutical ingredients and their pre-cursors for the global branded and generic pharmaceutical industries. Archimica has manufacturing sites in the US, UK, Germany, France and Italy. During his tenure at Archimica, James recruited and led a new management team, and implemented a detailed strategic repositioning of the business. Archimica was sold to the Euticals group in 2011.

Prior to Archimica, James was a Managing Director at TowerBrook Capital Partners and a Partner at Soros Private Equity Partners. James began his career working in the mergers and acquisitions department of Morgan Stanley. James is an Honorary Fellow of Robinson College, University of Cambridge, and holds MA and MPhil degrees from the University of Cambridge.

Steve McCue has extensive international business and finance leadership experience gained across sectors such as specialty chemicals, electronics manufacturing and more recently high volume wholesale distribution. Prior to Cycle, Steve was Group CFO of Paris based, Euronext listed, Antalis SA, the leading distributor of paper, packaging and visual communication materials where he succeeded in establishing a new main shareholder for the business.

Prior to Antalis, Mr McCue spent 15 years with the large US privately held industrial corporate, JM Huber, across two divisions of the business. Initially, within the high volume electronics manufacturing business, he held senior financial and general management roles in Europe and Asia. Mr McCue then joined the speciality chemicals business, CP Kelco, a global leader in hydrocolloids, serving regulated markets such as food and pharma, where he held both finance leadership positions as well as managing a global product line as Global Business Director whilst living and working across a number of European countries.

Chikai (Kai) Lai is Cycle’s Vice President of US Operations. Mr. Lai is in charge of Cycle’s operations in United States, managing the P&L of Cycle’s US business including Cycle’s hub services and Cycle’s products, as well as Cycle’s business relationships with industry partners.

Since joining Cycle in 2014, Mr. Lai has played an important role in delivering Cycle’s innovative products to markets. He served in various functions, including Regulatory Affairs, ROW (ex-US) Commercial and Operations and Program Management.

Prior to Cycle, Mr. Lai worked in product development at TWi Pharmaceuticals, Inc. a Taiwan-based, US-focused pharmaceutical company focused on developing Paragraph IV and 505(b)(2) products.

Mr. Lai received both a B.Pharm. and an M.S. in Pharmaceutical Sciences from Taipei Medical University in Taiwan, and an M.Phil. in Bioscience Enterprise from University of Cambridge in the United Kingdom.
Mr. Lai currently serves as a member of the Board of Trustees of the CGD Society, a global leading patient advocacy group for Chronic Granulomatous Disease, as well as the Board of Trustees of Jeans for Genes Campaign.

Sarah Gowing is the Group General Counsel and Company Secretary of Cycle Group Holdings Limited, and a director of the operating companies, Cycle Pharmaceuticals Limited and Varsity Pharmaceuticals Limited.

Sarah joined Cycle in 2020, and brings a wealth of private, VC-backed, and public company experience to the role, having worked at both Acambis plc and Vectura plc in the healthcare sector.

Sarah is responsible for overseeing the Group legal and company secretarial functions, as well as compliance, and provides broad and industry specific commercial experience and expertise to the Group.